March 23–25, 2026 | The Westin San Diego Bayview
Achieving durable responses in patients remains one of the most critical challenges for innate cell therapies, particularly as researchers work to overcome tumor escape and NK cell exhaustion. As the industry seeks to move beyond the limitations of singular genetic engineering, there is an increasing shift toward therapeutic strategies that prioritize biological synergy and natural immune coordination.
At the 11th Annual Innate Killer Summit, Alloplex Biotherapeutics’ CEO and Scientific Founder, Dr. Frank Borriello, MD, PhD, will discuss clinical and mechanistic findings that demonstrate how the company’s ENLIST immune cell training platform addresses these hurdles across a broad range of oncology indications.
ENLIST is an ex vivo process designed to activate peripheral blood mononuclear cells (PBMCs) to enhance both cytolytic activity and antigen-presenting cell (APC) function. This produces SUPLEXA cells—a non-engineered, autologous therapy with a hybrid immune phenotype and broad anti-tumor activity that has demonstrated efficacy in both solid tumors and hematologic malignancies.
During the Summit, Dr. Borriello will participate in two key sessions on Wednesday, March 25:
The discussion will build on observations from Alloplex’s completed Phase 1 clinical trial, where SUPLEXA cells demonstrated a pristine safety profile—with zero drug-related SAEs—and durable single-agent antitumor activity, including a median of 70+ weeks of stable disease in heavily pre-treated patients. Notably, clinical findings suggest a fundamental re-regulation of the host immune environment, characterized by the modulation of myeloid-derived suppressor cells (MDSCs).
Summit attendees are invited to join these sessions and engage in discussion regarding the implications of these data for pan-cancer treatment, immune cell platform development, and partnering opportunities.
Dr. Borriello also looks forward to speaking with attendees who have interest in opportunities to collaborate on Alloplex’s first-of-its-kind lead autologous platform, which features readily-scalable manufacturing designed in from inception.
Those interested in meeting with Dr. Borriello during the Summit are encouraged to reach out to the Alloplex team in advance or visit his Official Summit Speaker Profile for session locations and full abstract details.